Aug 20, 2017

Rare Disease Report Covers Alexion-GNS REFS Licensing Agreement


Rare Disease Treatments to Be Discovered by Machine Learning and Simulation Platform

August 10, 2017 – Earlier today, Alexion Pharmaceuticals was granted the licensing rights to operate GNS Healthcare’s Reverse Engineering and Forward Simulation (REFS) casual machine learning and simulation platform.
Alexion intends to use the platform to accelerate both the research of rare diseases and the development of novel therapies. Earlier this year, it was instrumental in finding a new target for breast cancer.
Read the full article here.